Oct 30, 2018 5:30 PM
Collaborators from the Department of Biomedical Informatics (DBMI) and Huntsman Cancer Institute (HCI) met on Tuesday to celebrate the very successful and ongoing partnerships between colleagues at the two institutions.
Mary Beckerle, the CEO of HCI, expressed how thrilled she was with the incredible capabilities DBMI has and has seen an explosion of potential for future collaboration. There is such a synergy between cancer science and informatics work at the University of Utah. HCI and DBMI are not only impacting care in Utah but are leading the nation in translating research to practice through standards enabled EHR apps.
- U24 NCI grant (Guilherme Del Fiol and Ken Kawamoto, co-PIs) focused on population-based CDS to identify patients who meet criteria for genetic evaluation of breast and colorectal cancer risk. Collaborators include DBMI (Charlene Weir, Wendy Chapman), Huntsman Cancer Institute (Josh Schiffman, Wendy Kohlmann), Internal Medicine (Rachel Hess, Michael Flynn), and Intermountain (Scott Narus).
- UO1 NCI grant in collaboration with the Huntsman Cancer Institute (Wendy Kohlmann and Kim Kaphingst, co-PIs; Ken Kawamoto and Guilherme Del Fiol, co-Is). In a multi-site randomized controlled trial (University of Utah and NYU), the study will compare two EHR-based interventions to identify and manage familial breast and colorectal cancer risk for patients who meet guideline-based criteria for further evaluation.
- $9.7 million PCORI grant in collaboration with the Huntsman Cancer Institute (David Wetter, PI). Through a randomized controlled trial, the study will assess the effect of CDS interventions for tobacco cessation in federally qualified health centers that provide care for underserved communities throughout Utah. Several members of the Reimagine EHR Initiative are co-investigators in the project (Guilherme Del Fiol, Bryan Gibson, Charlene Weir, Ken Kawamoto, and Damian Borbolla).
- F99/K00 NCI grant (Rosalie Waller PI, Nicola Camp and Guilherme Del Fiol primary F99 mentors) focused on bridging translational gaps in genetic risk for complex cancers. The grant provides Rosalie with up to 6 years of career development funding to train in both discovery of novel genes involved in complex cancers and implementation of genetic findings in the clinic.